Ring sideroblasts (RS) are erythroid precursors in which after Prussian blue staining (Perls reaction) there are a minimum of five siderotic granules covering at least a third of the nuclear circumference (Figure 1 ).
| Non-clonal sideroblastic anemias
These are inherited or acquired, non-clonal conditions that give rise to BM RS. Acquired conditions include excess alcohol use, copper deficiency, lead and zinc toxicity, and drugs such as isoniazid, chloramphenicol, penicillamine, and linezolid (Table 1) . 3, 4 Genetically defined congenital sideroblastic anemias can be attributed to mutations in 1 of 3 mitochondrial pathways: heme synthesis, iron-sulfur cluster biogenesis, and protein synthesis, or, rarely, i. X-linked sideroblastic anemia-ALAS2 mutations ii. SLC25A38 related sideroblastic anemia iii. Glutaredoxin 5 (GLRX5) related sideroblastic anemia iv. Congenital sideroblastic anemia without identified molecular defects v. Sideroblastic anemia as a component of genetic syndromes I. X-linked sideroblastic anemia with ataxia-ABCB7 mutations II. Kearns Sayre syndrome III. Myopathy, lactic acidosis, and sideroblastic anemia IV. Sideroblastic anemia, B cell immunodeficiency, periodic fevers, and developmental delay V. Pearson marrow-pancreas syndrome VI. Thiamine-responsive megaloblastic anemia syndrome VII. Congenital sideroblastic anemia due to NDUFB11 mutations.
Myeloproliferative neoplasms (MPN)
i. Essential Thrombocythemia with ring sideroblasts ii. Primary myelofibrosis with ring sideroblasts Zinc toxicity a mutation in a protein involved in mitochondrial respiration itself. 8 The most common CSA is the X-linked sideroblastic anemia (XLSA) occurring secondary to heterogenous, usually missense substitutions of conserved amino acids in the delta-aminolevulinate synthase 2 gene (ALAS2) 9 ; a gene encoding the first enzyme of the heme biosynthetic pathway. The activity of ALAS2 is pyridoxal 5-phosphatedependant, with mutations that decrease the binding of the pyridoxal phosphate cofactor accounting for the pyridoxine responsiveness seen in some patients. Affected individuals usually have a microcytic hypochromic anemia and then eventually go on to develop signs and symptoms of iron overload (hemosiderosis). 3 Loss of function mutations in SLC25A38 have been shown to cause a sideroblastic anemia (SA) similar to XLSA, but with an autosomal recessive inheritance. 10 XLSA with ataxia is an inherited disorder associated with SA and non-progressive spinocerebellar ataxia (cerebellar hypoplasia), secondary to mutations involving the ATP-binding cassette subfamily B member 7 (ABCB7). 11 Similarly, mutations involving glutaredoxin-5 (GLRX5), a gene that encodes a mitochondrial protein involved in iron-sulfur cluster biogenesis can give rise to CSA. 12 Recently, a recurring mutation in NDUFB11 (nuclear-encoded mitochondrial complex I protein) essential for mitochondrial oxidative phosphorylation was identified in 5 individuals from 4 families with variably syndromic, normocytic CSA. 8 Additional rare causes of CSA have been outlined in table one and include mitochondrial deletion syndromes (more common in pediatric patients). Gene sequencing, including mitochondrial DNA sequencing and the establishment of heteroplasmy are becoming more accessible, leading to the availability of better diagnostic tests for these conditions.
| Clonal sideroblastic anemias
Two clonal myeloid disorders characteristically associated with anemia and BM RS include RARS (now referred to as MDS-RS-single lineage
dysplasia) and RARS-T (now referred to as MDS/MPN-RS-T). The
World Health Organization (WHO) criteria for the diagnosis of MDS-RS used to necessitate the presence of 15% BM RS, 1 a criterion that was thought to be arbitrary and one without prognostic relevance. 13 In a study with 200 MDS patients without excess blasts and with 1%
RS, the impact of RS% was assessed both as a continuous and categorical variable: <5% (n 5 56), 5%-14% (n 5 32), 15%-50% (n 5 79), and >50% (n 5 33). 13 Ring sideroblast % correlated (P < 0. 
MDS-RS is further subclassified into two groups; MDS-RS with single lineage dysplasia (SLD; formerly RARS) and MDS-RS with multilineage dysplasia (MLD; formerly RCMD-RS). 2 MDS-RS-SLD
constitutes approximately 3%-10% of all cases of MDS and has a median age of presentation of 71 years, with a slight male preponderance. [14] [15] [16] Clonal cytogenetic changes can be seen in 5%-20% of cases, and when present usually involve a single chromosome. 16 MDS-RS-MLD is characterized by bicytopenia or pancytopenia, and dysplasia affecting >10% of the cells in two or more myeloid cell lineages. 1,2 Clinically these patients have a shorter OS with a higher risk for leukemic transformation (LT), in comparison to patients with MDS-RS-SLD. 14 
| Mutations and prognosis in MDS-RS
In 2011, with the advent of next generation sequencing (NGS) technology, somatic spliceosome component mutations (SF3B1-2q33.1,
U2AF2-19q13.42) were first described in patients with MDS (Table   2) . 17, 18 Among these, SF3B1 (splicing factor 3B subunit 1) mutations were most common in patients with MDS-RS. 14, 17, 18 The SF3B1 pro- The molecular mechanism behind the development of RS in relation to SF3B1 mutations is unclear. One hypothesis is that SF3B1 mutations could alter ABCB7 gene expression, dysregulating mitochondrial iron homeostasis, resulting in the formation of RS. 21 Currently, SF3B1
mutations have a positive predictive value for disease phenotype with RS of 97.7% (95% CI, 93.5%-99.5%), and conversely the absence of these mutations, have a negative predictive value of 97.8% (95% CI, 93.8%-99.5%). 22 It is important to note that SF3B1 mutations can be seen in a variety of myeloid neoplasms with BM RS such as; MDS/ MPN-RS-T (80%), primary myelofibrosis (PMF7%) and chronic myelomonocytic leukemia (CMML6%). [23] [24] [25] [26] They have also been described in non-myeloid cancers such as, chronic lymphocytic leukemia (CLL15%, enriched in patients with del11q), where they are associated with an adverse prognostic impact. 27 The prognostic impact of SF3B1 mutations in MDS-RS is somewhat controversial, with a few reports demonstrating a favorable independent prognostic impact, 22 with most others not confirming the same. 14, 28, 29 In the Mayo Clinic study, we studied 107 patients with
MDS-RS, including 48 with MDS-RS-SLD (RARS), 43 with MDS-RS-
MLD (RCMD-RS), 11 with refractory anemia with excess blasts-1 (RAEB1)-RS, and 5 with RAEB2-RS. 14 SF3B1 mutations were detected in 53 (50%) patients: 35 MDS-RS-SLD (73%), 16 MDS-RS-MLD (37%), and 2 RAEB1-RS (18%). In univariate analysis, the presence of SF3B1 mutations was associated with better OS (P < 0.01) and LFS (P < 0.01); however, in both instances, significance was completely accounted for by WHO morphologic risk categorization. 14 nostic scoring system-LR-PSS), SF3B1 mutations were seen in 78% of patients with BM RS, they frequently co-occurred with DNMT3A mutations (P < 0.001) and did not impact OS or LFS. 29 In this study, gene mutations associated with an independent prognostic impact in patients with MDS included; EZH2, RUNX1, Tp53, and ASXL1. Of these, only EZH2 mutations retained significance in a multivariable model that included LR-PSS and the aforementioned mutations. 29 Thus conventional prognostication of patients with MDS-RS is usually carried out using MDS based risk stratification systems such as the IPSS (international prognostic scoring system), 30 revised IPSS (R-IPSS), 31 MD LR-PSS, 32 and the WPSS (WHO classification based prognostic scoring system). 33 Additional prognostic strategies incorporating molecular aberrations with clinical parameters are currently evolving. 34 
| Clinical outcomes
Patients with MDS-RS are generally stratified into lower risk categories using the aforementioned MDS prognostic models. 
| Iron chelation therapy
The indolent nature of MDS-RS, coupled with infective erythropoiesis and red cell TD, can result in iron overload. 51 The iron status can be monitored non-invasively by measuring serum ferritin levels, transferrin saturation and by the utilization of T2* MRI (magnetic resonance imaging) scans. 51, 52 Increased serum ferritin levels in MDS, can be secondary to TD, cancer-associated inflammation (acute phase reactant) and liver disease. [53] [54] [55] Each of these comorbidities are prognostically detrimental and it is unclear if iron overload, or for that matter an elevated ferritin level, per se contribute to mortality and morbidity. [53] [54] [55] Data suggesting hemosiderosis-related causes of death in MDS are scant and are limited to case reports. In a retrospective study of 126 MDS-RS patients, independent prognosticators for survival included, IPSS (P < 0.0001) categories and red cell TD at diagnosis (P 5 0.001), but not the number of red cell units transfused during the disease course (P 50.17). 53 There were no correlations between survival and serum ferritin level, measured either at diagnosis or during follow-up. Similarly, there was no difference in survival when patients were stratified by serum ferritin levels of < or 1000 ng/mL at diagnosis or peak serum ferritin levels of <1000, 1000-5000, or >5000 ng/mL during follow-up. 53 Similarly, in 88 patients with WHO defined MDS with isolated del(5q), serum ferritin levels did not impact survival and with a median OS of 66 months, with 66% deaths documented at last follow up, there were no deaths attributed to iron overload. 56 A recent prospective study also found no impact of an elevated liver iron content, as measured by MRI scans, on post allogeneic stem cell transplant (HSCT) survival and outcomes. 57 Additionally, iron chelation agents such as desferrioxamine (parenteral), deferiprone and deferasirox (both oral) are expensive and are associated with side effects. 58 Desferrioxamine has been associated with deafness and visual side effects, 52 deferiprone with gastrointestinal (GI) side effects and agranulocytosis, 59 and deferasirox with renal failure, liver failure, cytopenias and GI side effects. 60 The use of iron chelation therapy in MDS-RS awaits rigorous prospective evaluation and until this can be established, its routine use cannot be recommended.
| Hypomethylating agent use
The upfront use of hypomethylating agents (HMA) such as 5- 
| Imetelstat
The telomerase inhibitor imetelstat is an oligonucleotide that targets the RNA template of human telomerase reverse transcriptase. In a recent study, imetelstat produced clinical and molecular remissions in patients with myelofibrosis with SF3B1 or U2AF1 mutations; thus leading to its use in a pilot study for patients with MDS-RS (n 5 5) and MDS/MPN-RS-T (n 5 3). 65, 66 67 In addition, adjustment for quality of life did not change the preferred treatment strategy. In this study 16% of patients in the non-transplant group and approximately 5% in the transplant group had a morphological diagnosis of MDS-RS-SLD. 67 Similarly, in de novo lower risk MDS patients with ages between 60 and 70 years, OS was better with non-transplant strategies (77 months), in comparison to a RIC allo-HSCT (38 months). 68 Once again in this cohort quality-adjusted life expectancy did not alter preferred treatment strategy. In the non-transplant group, the lower risk MDS patients received ESA and supportive care, while the higher risk patients received HMA. 68 
| M Y E L O D Y S P L A S T I C / MYELOPROLIFERATIVE NEOPLASM WITH R I NG SIDE R OBLASTS AN D T H R O M B O C Y T O S

| Mutations and prognosis in MDS/MPN-RS-T
Gene mutations encountered in patients with MDS/MPN-RS-T include; SF3B1 (85%), JAK2V617F (50%), TET2 (25%), ASXL1
(20%), DNMT3A (15%), and SETBP1 (10%). 70, 71 In a recent
European study (n 5 92), gene mutations detected included;
spliceosome components -SF3B1290%, SRSF226.7%, U2AF125.3%, ZRSR222.7%, signalling pathways-JAK2V617F-57%, MPL22.7%, CBL24%, epigenetic regulators-ASXL1215%, TET2225%, EZH227%, DNMT3A215%, IDH224%, and transcription regulators-ETV622.7%, RUNX121.3%. 71 Approximately 50% of patients harbored both the JAK2V617F and SF3B1 mutations. Conversely, most of the SF3B1wt patients had JAK2V617F and ASXL1 mutations. 71 In a Mayo Clinic study, 94% of patients had 1 mutations; common mutations being: SF3B1 85%, JAK2V617F 33%, ASXL1 29%, DNMT3A 13%, SETBP1 13% and TET2 10%. 70 In a multivariable survival analysis (n 5 82), anemia (P 5 0.02), and abnormal karyotype (P 5 0.01) were independently prognostic for inferior survival. In patients with NGS information (n 5 48), univariate analysis showed association between poor survival and presence of SETBP1 (P 5 0.04) or ASXL1 (P 5 0.08) mutations whereas the absence of these mutations (ASXL1wt/SETBP1wt) was favorable (P 5 0.04); the number of concurrent mutations did not provide additional prognostication (P 5 0.3). 70 This resulted in a hazard ratio-weighted prognostic model, with 2 points for an abnormal karyotype, 1 point for either ASXL1 and/or SETBP1 mutations, and 1 point for a HB level < 10 g/dL, which effectively stratified patients into three risk categories; low (0 points), intermediate (1 point), and high (2 points), with median survivals of 80, 42, and 11 months respectively (P 5 0.01) ( Figure 5A ). 70 Mutations in exon 9 of the calreticulin gene (CALR) have been reported as mutually exclusive of JAK2 and MPL mutations and can be seen in 67%-71% of ET and 56%-88% of PMF patients with wild-type JAK2 or MPL. 
| Thrombosis in MDS/MPN-RS-T
The frequency of thrombotic events in MDS/MPN-RS-T is thought to be similar to that of ET (3.6 vs 3.9/100 patient-years), but more frequent than MDS-RS (3.6 vs 0.9/100 patient-years). 25 In a prior study (n 5 15), 6 of 10 (60%) patients with SF3B1mut RARS-T had thrombotic events; whereas there were no thrombotic events in SF3B1wt
patients. 19 In a recent Mayo Clinic study, at a median follow-up of 27 months, 48 (59%) deaths and 16 (20%) thrombotic events were documented (median OS 44 months). and CV risk factors (P 5 0.95) did not have prognostic impact. Given the association between SF3B1 mutations and BM RS, in a multivariable model that included these two as covariates, only the presence of SF3B1 mutations retained prognostic significance (P 5 0.02) (Fig- ure 5B). The presence of SF3B1 mutation remained significant (P 5 0.04) (hazard ratio-8.9; 95% confidence interval 1.1-4.5) when history of thrombosis (P 5 0.12) or hemoglobin <10 g/dL (P 5 0.14)
was introduced into the multivariable model. Thrombotic events occurring at or prior to diagnosis (P 5 0.53), thrombotic events occurring after diagnosis (P 5 0.69), SF3B1 (P 5 0.83) and JAK2V617F (P 5 0.4) mutational status, and CV risk factors (P 5 0.05) did not impact OS. 23 Thus, unlike in ET, prior thrombotic events in MDS/MPN-RS-T do not impact OS. 23 The mechanism by which SF3B1 mutations might increase thrombotic predisposition in patients with MDS/MPN-RS-T requires further study.
| Risk-adapted therapy
Given that, until recently, RARS-T was considered a provisional entity in the MDS/MPN overlap syndromes, no formal guidelines for the management of this disease exist. Current management strategies, including response criteria are extrapolated from related diseases such as low risk MDS-RS and MPN (ET). Management is individualized to address presenting problems ( Figure 6 ).
In patients with anemia, management is very similar to lower risk MDS, where the use of ESA and transfusional supportive care is instituted early on. There are case reports documenting the efficacy of lenalidomide in alleviating red cell transfusion need in patients with MDS/MPN-RS-T. 74 In one particular case report, of 2 patients with JAK2V617mut MDS/MPN-RS-T, lenalidomide was able to achieve a complete molecular remission in one patient. 74 Clinical trials with newer agents such as sotatercept/luspatercept, eltrombopag, and the novel telomerase inhibitor imetelstat are either in conception or are currently ongoing. factors) and high risk (1 or 2 factors), based on age >60 years and a prior thrombotic event ( Figure 6 ). 76 We believe (in the absence of extreme thrombocytosis) that low risk patients with MDS/MPN-RS-T benefit from low dose aspirin therapy (81-100 mg), with a reduction in the risk for arterial thrombosis and a significant reduction in microvascular/vasomotor symptoms. 77 Recent data, suggests an added benefit for twice daily aspirin dosing in patients with ET, a finding that needs to be explored in MDS/MPN-RS-T. 78 Alternative antiplatelet agents such as clopidogrel, prasugrel, and ticagrelor are considered in the setting of aspirin resistance, aspirin hypersensitivity or the need for dual antiplatelet therapy.
The value of cytoreductive therapy in MDS/MPN-RS-T is uncertain and its use might exacerbate anemia, which is the most frequent disease complication in MDS/MPN-RS-T. We therefore avoid the use of cytoreductive drugs in patients with anemia unless compelled by the presence of multiple risk factors for thrombosis. 76 Our drug of choice, if cytoreductive therapy is indicated, is hydroxyurea, which has been the mainstay of cytoreductive therapy, with randomized data in patients with ET demonstrating a significant reduction in thrombotic events. In a randomized study, after 27 months follow up, thrombotic events were seen in 3.6% of ET patients on hydroxyurea and in 24% of patients in the control arm. 79 Alternate cytoreductive agents that we consider in the setting of hydroxyurea failure, refractoriness or intolerance, include; lenalidomide, interferon alpha or busulfan. 76 Two recent studies of pegylated INF-a (90 mg SC weekly) in PV and ET reported hematologic remissions of 80% accompanied by decreases in JAK2V617F allele burden (complete molecular remission rate of 5-10%). 80, 81 In one of the two studies, 77 cases were evaluable after a median follow up of 21 months and 76% and 70% of patients with ET or PV, respectively, achieved a complete hematologic remission, mostly in the first 3 months; side effects were recorded in 96% of the patients and 22% had discontinued treatment. 81 A small study of busulfan in 36 patients with ET demonstrated safety and efficacy of the agent, without an increase in LT rates. 82 In the setting of extreme thrombocytosis, the diagnosis of acquired von Willebrand's disease should be evaluated for, using the ristocetin cofactor activity and the von Willebrand's factor multimer analysis. 76 Affected patients demonstrate an improvement in bleeding parameters after a reduction in the platelet count is achieved with cytoreductive agents.
Similar to lower risk MDS and MPN patients, allo-HSCT is reserved for patients with refractory cytopenias or progressive disease. The risks 
